Category: Press Release - Page 78 - Psychedelic Alpha

Read more about the article Filament Health and Cybin Therapeutics Announce Licensing Agreement

Filament Health and Cybin Therapeutics Announce Licensing Agreement

Post published:January 17, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Post published:January 17, 2022
Post category:Press Release

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Post published:January 14, 2022
Post category:Press Release

Read more about the article PharmaDrug Announces Resignation of Director

PharmaDrug Announces Resignation of Director

Post published:January 13, 2022
Post category:Press Release

Read more about the article Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

Post published:January 13, 2022
Post category:Press Release

Read more about the article Nova Mentis Provides Corporate Update – 2022 Planned Catalysts

Nova Mentis Provides Corporate Update – 2022 Planned Catalysts

Post published:January 12, 2022
Post category:Press Release

Read more about the article MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

Post published:January 12, 2022
Post category:Press Release

Read more about the article atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

Post published:January 12, 2022
Post category:Press Release

Read more about the article PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

Post published:January 12, 2022
Post category:Press Release

Read more about the article Wesana Health Provides Strategic and Operational Updates

Wesana Health Provides Strategic and Operational Updates

Post published:January 12, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.